Ramucirumab in metastatic renal cell carcinoma: The beginning or the end?

    loading  Checking for direct PDF access through Ovid

Abstract

The current editorial focuses on a phase 2 study evaluating ramucirumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior sunitinib and/or sorafenib therapy. The potential for further development is discussed in the context of the rapidly changing landscape of therapy for mRCC.

Related Topics

    loading  Loading Related Articles